SynAct Pharma AB (“SynAct”) today announced that the clinical study of AP1189 has begun and that the first healthy subjects have been dosed. AP1189 is being developed as a new potential treatment for psoriatic arthritis, a form of joint disorder that affects approximately 30 percent of patients suffering from psoriasis.
In May 2017, SynAct received all the approvals required to start the Clinical Phase I study and has now dosed the first participants. The primary purpose of the study, which is being conducted in Belgium, is to evaluate the safety and tolerability of the candidate drug AP1189 in healthy subjects and to study its pharmacokinetics, i.e. How it is absorbed and metabolized (broken down) in the body. Initially, AP1189, which is taken orally, will be given in single ascending doses. In the second phase of the study, AP1189 will be given for up to 14 days in ascending daily doses. Furthermore, food interaction will be studied, i.e. how food may affect the uptake of AP1189 by the body. The study covers up to 108 healthy test subjects and results from the study are expected to be presented in the First Quarter of 2018.
CEO Jeppe Øvlesen comments
“We are pleased to announce that we have now dosed the first participants in our Clinical Phase I study of AP1189. This is a big and important milestone for the company and we are pleased to have now started the clinical study. The results of the Phase I study will provide both the company and potential commercial partners with valuable information for the further development of AP1189.”
This is information that SynAct Pharma AB is obliged to disclose under the EU’s market abuse regulation. The information was submitted by the above contact person for publication on 7 June 2017.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen Thomas Jonassen
CEO, SynAct Pharma AB CSO, SynAct Pharma AB